Figure 2. Loss of SRV2 attenuates cardiomyocyte death and reduces inflammation response in LPS-induced septic cardiomyopathy. (A) Cardiomyocyte viability was measured via MTT assay after transfection of siRNA against SRV2. (B–C) TUNEL staining was used to evaluate numbers of apoptotic cardiomyocytes after SRV2 siRNA transfection. (D) An LDH release assay was used to examine cardiomyocyte damage in response to LPS treatment and after SRV2 siRNA transfection cardiomyocytes. (E–H) RNA was isolated from LPS-treated cardiomyocytes and qPCR was performed to analyze IL-1β, IL-8, TNF-α, and MCP-1 transcript levels. *p<0.05 vs. control group, #p<0.05 vs. LPS group.